ID   KTCTL-26A
AC   CVCL_5873
SY   KTCTL-26a; KTCTL26A; RCC-FG2; RCCFG2
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 995
DR   cancercelllines; CVCL_5873
DR   Cell_Model_Passport; SIDM00819
DR   CLS; 300249
DR   Cosmic; 972924
DR   Cosmic; 1352061
DR   Cosmic; 1751972
DR   Cosmic-CLP; 1524414
DR   DepMap; ACH-002189
DR   EGA; EGAS00001000978
DR   GDSC; 1524414
DR   GEO; GSM1670362
DR   PharmacoDB; RCCFG2_1289_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54900643
RX   PubMed=7828150;
RX   PubMed=7915601;
RX   PubMed=8086765;
RX   PubMed=27397505;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31267758;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Instable (MSI-low) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Phe148Leufs*11 (c.444delT); ClinVar=VCV000223212; Zygosity=Unspecified (PubMed=7915601).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.87%; East Asian, North=1.55%; East Asian, South=0%; South Asian=1.66%; European, North=66.58%; European, South=29.34% (PubMed=30894373).
CC   Misspelling: KTCL26A; Cosmic=972924; PubMed=7915601.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
ST   Source(s): CLS; Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 11,12
ST   D16S539: 11,13
ST   D18S51: 15,17
ST   D21S11: 29,30
ST   D3S1358: 16
ST   D5S818: 10,12
ST   D7S820: 11,12
ST   D8S1179: 12,15
ST   FGA: 19,23
ST   Penta D: 9,13
ST   Penta E: 12,18
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 18,19
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5872 ! KTCTL-26
SX   Male
AG   77Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 31
//
RX   PubMed=7828150; DOI=10.1016/0165-4608(94)90087-6;
RA   Hogemann I., Bock S., Heppner P., Petrides P.E.;
RT   "Cytogenetic and growth factor gene analysis of a renal carcinoma cell
RT   line.";
RL   Cancer Genet. Cytogenet. 78:175-180(1994).
//
RX   PubMed=7915601; DOI=10.1038/ng0594-85;
RA   Gnarra J.R., Tory K., Weng Y., Schmidt L.S., Wei M.H., Li H., Latif F.,
RA   Liu S., Chen F., Duh F.-M., Lubensky I.A., Duan D.R., Florence C.,
RA   Pozzatti R., Walther M.M., Bander N.H., Grossman H.B., Brauch H.,
RA   Pomer S., Brooks J.D., Isaacs W.B., Lerman M.I., Zbar B.,
RA   Linehan W.M.;
RT   "Mutations of the VHL tumour suppressor gene in renal carcinoma.";
RL   Nat. Genet. 7:85-90(1994).
//
RX   PubMed=8086765; DOI=10.1007/BF00252823;
RA   Gross A.J., Wolff M., Fandrey J., Miersch W.-D., Dieckmann K.-P.,
RA   Jelkmann W.;
RT   "Prevalence of paraneoplastic erythropoietin production by renal cell
RT   carcinomas.";
RL   Clin. Investig. 72:337-340(1994).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31267758; DOI=10.2217/fon-2019-0067;
RA   Nogueira I., Dias F., Morais M., Teixeira A.L., Medeiros R.;
RT   "Everolimus resistance in clear cell renal cell carcinoma: miRNA-101
RT   and HIF-2alpha as molecular triggers?";
RL   Future Oncol. 15:2361-2370(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//